Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | STX-0712 |
| Synonyms | |
| Therapy Description |
STX-0712 is a cytotoxicity targeting chimera targeting CCR2, which potentially induces killing of CCR2-positive tumor cells (Blood (2024) 144 (Supplement 1): 1380, Blood (2024) 144 (Supplement 1): 2771). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| STX-0712 | STX 0712|STX0712 | STX-0712 is a cytotoxicity targeting chimera targeting CCR2, which potentially induces killing of CCR2-positive tumor cells (Blood (2024) 144 (Supplement 1): 1380, Blood (2024) 144 (Supplement 1): 2771). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06950034 | Phase I | STX-0712 | A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) | Recruiting | USA | 0 |